Kisspeptin-10

One of the more surprising findings about Kp-10 is its role in bone. As we age, osteoclasts — the cells that break down old bone — become overactive, tipping the balance toward net bone loss. A 2024 study published in Nature Communications identified a direct mechanism by which Kp-10 may counteract this process (1).

The research showed that when Kp-10 binds to GPR54 on osteoclasts, it triggers the upregulation of an enzyme called Dusp18. That enzyme then dephosphorylates Src — a kinase that osteoclasts depend on to function. Without active Src, osteoclasts can't efficiently resorb bone. In effect, Kp-10 turns down the volume on the cells that drive bone loss. Subjects lacking the kisspeptin gene, the GPR54 receptor, or Dusp18 all showed hyperactive osteoclasts and bone loss, while administered Kp-10 reversed bone loss in trials by suppressing osteoclast activity (1).

This identifies the Kp-10/GPR54/Dusp18/Src axis as a potentially druggable pathway for conditions involving excess bone resorption, and it positions Kisspeptin-10 as more than a reproductive hormone — it's a signaling molecule with direct effects on skeletal maintenance.

Kp-10 also appears to influence how cardiac tissue handles collagen — the structural protein that gives the heart its mechanical integrity. A 2023 study examined Kisspeptin-10's effects on cardiac fibroblasts, the cells responsible for producing and maintaining the heart's connective tissue scaffold (2).

Kp-10 significantly increased intracellular collagen content in cardiac fibroblasts and elevated levels of phosphorylated focal adhesion kinase (FAK), a signaling protein that helps cells respond to mechanical stress. The peptide raised the production of procollagen precursors while simultaneously reducing the release of matrix metalloproteinases (MMP-1, -2, and -9) — the enzymes that break collagen down — and increasing their tissue inhibitors (TIMP-1, -2, and -4). The net effect was a tilt toward collagen accumulation (2).

When FAK was blocked, Kp-10's effects disappeared, identifying FAK as the central mediator. Notably, the pathway operated independently of TGF-β1, the canonical fibrosis signal — suggesting Kp-10 represents a distinct route to influencing cardiac matrix biology. This finding cuts both ways: it points to potential utility for tissue repair contexts but also raises questions about over-deposition, which is why researchers continue mapping the conditions under which the effect is beneficial versus excessive.

Kp-10 has also been studied in the context of neurodegeneration, specifically for its potential to protect neurons from the toxic effects of misfolded proteins. A 2022 study examined whether Kisspeptin-10 could shield cholinergic neurons — the cell type most affected in dementia with Lewy bodies and related conditions — from damage caused by α-synuclein, a protein that aggregates pathologically in these diseases (3).

In cholinergic-differentiated neuronal cells, low concentrations of Kp-10 (0.01 to 1 µM) substantially suppressed the toxicity of both wild-type and a mutant form (E46K) of α-synuclein. Higher concentrations (10 µM) had the opposite effect and reduced cell viability, indicating a tight dose window. Computational modeling using molecular docking and dynamics simulations suggested Kp-10 binds favorably to the C-terminal region of α-synuclein, the same region implicated in its aggregation behavior (3).

The authors propose Kp-10 may serve as a structural scaffold for designing molecules that interfere with α-synuclein toxicity — an approach that, if validated in further work, could open new avenues in neurodegeneration research.

Given that the kisspeptin system was originally characterized as the upstream switch for the reproductive hormone axis, much of the research on Kp-10 still centers on reproductive tissues — but in increasingly granular ways.

A study tracking serum Kp-10 across pregnancy found that levels follow a distinct pattern: an early plateau, a rise around mid-gestation, a dip, then a second rise approaching term, with concentrations correlating with cortisol and estradiol patterns (4). The authors interpret this as Kp-10 helping to maintain the endocrine balance required to sustain pregnancy.

At the cellular level, Kp-10 has been shown to promote progesterone synthesis in ovarian granulosa cells by downregulating a microRNA (miR-1246) that normally suppresses StAR, a key gene in steroid hormone production (6). By lifting that brake, Kp-10 increases free cholesterol availability and progesterone output.

Kp-10 has also been investigated as an additive to sperm cryopreservation media. At doses of 15–20 µmol/L, it improved post-thaw motility, membrane integrity, acrosome integrity, and DNA integrity while raising antioxidant enzyme levels and reducing lipid peroxidation (5). This points to an antioxidant-protective dimension to Kp-10's activity in reproductive cells under stress.

Reported side effects of Kisspeptin-10 in the published research are minimal, and no significant adverse effects have been described in the studies summarized here (1, 2, 3). One consistent observation across the literature is that Kp-10 appears to operate within a relatively tight dose window — low concentrations show protective or beneficial effects, while high concentrations can produce the opposite outcome, as seen in the neuronal study where 10 µM reduced cell viability (3). This biphasic pattern is worth noting for researchers planning experimental work.

Long-term safety in humans hasn't been formally characterized, and the peptide's broad signaling reach — touching reproductive, skeletal, cardiac, and neural systems — means downstream effects may be context-dependent.

The body of Kisspeptin-10 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.